Clinical Trials Logo
  1. Home
  2. Lentigo Maligna
  3. NCT02306512

Mohs and Immunofluorescence for Malignant Melanoma In Situ

Lentigo Maligna Clinical Trial

Official title:
Mohs Micrographic Surgery for Primary Cutaneous Malignant Melanoma In Situ Using Immunofluorescence

Clinical Trial Summary

The purpose of this study is to determine if immunofluorescence (IF) can effectively identify features of malignant melanoma in situ, on sun-damaged skin, in the setting of Mohs Micrographic Surgery.

Clinical Trial Description

The aim of this study is to

1. Determine the feasibility of using melanocytic markers such as Melanoma antigen recognized by T cells 1 (MART-1) with fluorescence to clear surgical margins when compared to conventional MART-1 immunohistochemistry (IHC) in the setting of MMS for LM (lentigo maligna type melanoma in situ).

2. Compare the use of a cocktail of immunofluorescent markers such as, but not limited to, Sex-determining Region Y (SRY)-box 10 (SOX10), human melanoma black 45 (HMB-45), and Kiel-67 (Ki-67) to sections only stained with fluorescent MART-1 alone.

3. Explore the value of using other combinations of immunofluorescent markers such as S-100 with Microphthalmia-associated transcription factor (MiTF), Nestin with Ki-67, and HMB-45 with Lamin. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02306512
Study type Interventional
Source University of Miami
Contact
Status Withdrawn
Phase N/A
Start date June 2015
Completion date November 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT06046144 - Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors
Completed NCT00707174 - Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna N/A
Completed NCT03508297 - Reflectance Confocal Microscopy to Diagnose MM & LM
Completed NCT01161888 - Effect of Topical Imiquimod on Lentigo Maligna Phase 4
Completed NCT02723721 - Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face Phase 2
Terminated NCT04688749 - Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage
Active, not recruiting NCT01088737 - Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna Phase 2/Phase 3
Completed NCT02685592 - Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Phase 4
Active, not recruiting NCT02394132 - Radiotherapy or Imiquimod in Complex Lentigo Maligna Phase 3
Completed NCT00785369 - In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis N/A
Recruiting NCT06014619 - Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs